Other photosensitizing agents that could increase the potential for skin photosensitivity reactions.
Source: NLP:verteporfin for injection
Verteporfin For Injection Interactions
Brand names: Visudyne
Photoenhancer · Photoabsorption
Route: Intravenous
Contraindications
4 CONTRAINDICATIONS VISUDYNE (verteporfin for injection) is contraindicated for patients with porphyria or a known hypersensitivity to any component of this preparation [see Adverse Reactions ( 6 )] . VISUDYNE (verteporfin for injection) is contraindicated for patients with porphyria or a known hypersensitivity to any component of this preparation. ( 4 )
Pregnancy & Breastfeeding
8.1 Pregnancy Risk Summary There are no data with the use of VISUDYNE in pregnant women to inform a drug-associated risk. Intravenous administration of verteporfin to pregnant rats during the period of organogenesis produced an increase in the incidence of anophthalmia/microphthalmia and wavy ribs at exposures approximately 40-fold the human exposure at the recommended clinical dose. Verteporfin did not produce adverse fetal effect in rats or rabbits at exposures 6- to 20-fold the human exposure at the recommended clinical dose. There are no adequate and well-controlled studies in pregnant women. VISUDYNE should be used during pregnancy only if the benefit justifies the potential risk to the fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively. Data Animal Data Rat fetuses of dams administered verteporfin for injection intravenously during organogenesis exhibited an increase in the incidence of anophthalmia/microphthalmia and wavy ribs at doses ≥10 mg/kg/day (approximately 40-fold the human exposure at the recommended dose of 6 mg/m 2 , based on AUC in female rats). No teratogenic effects were observed in rat fetuses at a dose of 2 mg/kg/day (approximately 6-fold the human exposure at the recommended dose of 6 mg/m 2 , based on AUC in female rats). In pregnant rabbits, a decrease in maternal body weight gain and food consumption was observed in animals that received verteporfin for injection intravenously at doses up to 10 mg/kg/day during organogenesis. The no observed adverse effect level (NOAEL) for maternal toxicity was 3 mg/kg/day (approximately 6-fold the recommended human dose of 6 mg/m 2 , based on body surface area). No teratogenic effects were observed in rabbit fetuses at doses up to 10 mg/kg/day (approximately 20-fold the recommended human dose of 6 mg/m 2 , based on body surface area).
14 interactions on record
Compounds that quench active oxygen species or scavenge radicals would be expected to decrease VISUDYNE activity.
Source: NLP:verteporfin for injection
Other photosensitizing agents that could increase the potential for skin photosensitivity reactions.
Source: NLP:verteporfin for injection
Could enhance the rate of VISUDYNE uptake by the vascular endothelium, potentially increasing photodynamic effects.
Source: NLP:verteporfin for injection
Verteporfin For Injection + DmsoModerate
Compounds that quench active oxygen species or scavenge radicals would be expected to decrease VISUDYNE activity.
Source: NLP:verteporfin for injection
Compounds that quench active oxygen species or scavenge radicals would be expected to decrease VISUDYNE activity.
Source: NLP:verteporfin for injection
Other photosensitizing agents that could increase the potential for skin photosensitivity reactions.
Source: NLP:verteporfin for injection
Compounds that quench active oxygen species or scavenge radicals would be expected to decrease VISUDYNE activity.
Source: NLP:verteporfin for injection
Compounds that quench active oxygen species or scavenge radicals would be expected to decrease VISUDYNE activity.
Source: NLP:verteporfin for injection
Other photosensitizing agents that could increase the potential for skin photosensitivity reactions.
Source: NLP:verteporfin for injection
Could enhance the rate of VISUDYNE uptake by the vascular endothelium, potentially increasing photodynamic effects.
Source: NLP:verteporfin for injection
Other photosensitizing agents that could increase the potential for skin photosensitivity reactions.
Source: NLP:verteporfin for injection
Other photosensitizing agents that could increase the potential for skin photosensitivity reactions.
Source: NLP:verteporfin for injection
Drugs that decrease clotting, vasoconstriction or platelet aggregation could decrease the efficacy of VISUDYNE therapy.
Source: NLP:verteporfin for injection